Safety and Feasibility of Vulvar Cancer Treatment with Electrochemotherapy.

bleomycin electrochemotherapy electroporation feasibility safety vulvar cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Jun 2023
Historique:
received: 16 05 2023
revised: 04 06 2023
accepted: 05 06 2023
medline: 28 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Electrochemotherapy is a local ablative therapy used for the treatment of various superficial and deep-seated tumors. Electrochemotherapy involves the application of electric pulses locally to tumors to destabilize cell membranes and facilitate the entry of cytotoxic drugs, thereby enhancing their cytotoxicity locally. The aim of our study is to investigate the safety and feasibility of electrochemotherapy in patients with vulvar cancer recurrence used for nonpalliative purposes. Ten patients with single local vulvar cancer recurrence were treated with intravenous bleomycin, followed by a local application of electric pulses (electrochemotherapy) to the tumor. Adverse events were determined using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The feasibility of treating vulvar cancer with electrochemotherapy was determined by an appropriate selection of electrodes based on the size and location of the tumor with safety margins included. Electrochemotherapy was feasible in all patients. No electrochemotherapy-related or other serious adverse events occurred. Our data suggest that electrochemotherapy is a feasible and safe technique for the treatment of vulvar cancer recurrence for nonpalliative purposes. Based on our results, electrochemotherapy might be a viable therapeutic tool for patients who would otherwise undergo surgery involving a mutilation of the external genitalia.

Identifiants

pubmed: 37370690
pii: cancers15123079
doi: 10.3390/cancers15123079
pmc: PMC10296599
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Slovenian Research Agency
ID : P3-0003

Références

Cancers (Basel). 2022 Apr 30;14(9):
pubmed: 35565394
Cancers (Basel). 2022 May 09;14(9):
pubmed: 35565474
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221116489
pubmed: 35899313
Cancers (Basel). 2021 Apr 01;13(7):
pubmed: 33915692
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
Ann Oncol. 2019 Dec 1;30(12):1884-1901
pubmed: 31566661
Cancer. 1998 Jul 1;83(1):148-57
pubmed: 9655305
J Am Acad Dermatol. 2019 Dec;81(6):1387-1396
pubmed: 31349045
Gynecol Oncol. 2019 Jan;152(1):151-156
pubmed: 30414740
Arch Gynecol Obstet. 2019 Jul;300(1):161-168
pubmed: 31011878
Cancers (Basel). 2022 Aug 29;14(17):
pubmed: 36077719
Radiology. 2020 May;295(2):254-272
pubmed: 32208094
Int J Gynecol Cancer. 2020 Jul;30(7):939-946
pubmed: 32474450
Acta Oncol. 2012 Jul;51(6):713-21
pubmed: 22731832
Eur J Surg Oncol. 2019 Dec;45(12):2257-2267
pubmed: 31285093
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Gynecol Oncol. 2017 Feb;144(2):438-447
pubmed: 28034465
Radiol Oncol. 2015 Mar 03;49(1):71-4
pubmed: 25810704
Int J Gynecol Cancer. 2023 Apr 3;33(4):473-481
pubmed: 36787933
Cancers (Basel). 2019 May 12;11(5):
pubmed: 31083599
Br J Dermatol. 2017 Jun;176(6):1475-1485
pubmed: 28118487
Cancers (Basel). 2021 Dec 30;14(1):
pubmed: 35008331
Int J Cancer. 2017 Dec 1;141(11):2174-2186
pubmed: 28730615
J Surg Oncol. 2015 Oct;112(5):529-32
pubmed: 26345705
Biomed Eng Online. 2014 Mar 12;13(1):29
pubmed: 24621079
Gynecol Oncol. 2019 May;153(2):368-375
pubmed: 30792003
Cancers (Basel). 2020 Dec 15;12(12):
pubmed: 33333941
J Low Genit Tract Dis. 2022 Jan 1;26(1):38-42
pubmed: 34798652
Cancers (Basel). 2021 Dec 23;14(1):
pubmed: 35008225
Gynecol Oncol. 2013 Sep;130(3):550-3
pubmed: 23811116
Radiol Oncol. 2023 Feb 17;57(1):121-126
pubmed: 36795008
Int J Gynecol Cancer. 2020 Jul;30(7):927-931
pubmed: 32371425
J Obstet Gynaecol Res. 2022 Mar;48(3):533-540
pubmed: 34962334
Semin Oncol. 2019 Apr;46(2):173-191
pubmed: 31122761
Eur J Surg Oncol. 2014 Jul;40(7):875-82
pubmed: 24746935
Bioelectrochemistry. 2021 Oct;141:107871
pubmed: 34147013
J Clin Oncol. 2014 Oct 1;32(28):3144-55
pubmed: 25154827
Int J Gynecol Cancer. 2020 Jan;30(1):107-114
pubmed: 31801791

Auteurs

Gregor Vivod (G)

Department of Gynecological Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

Masa Bosnjak (M)

Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.

Nina Kovacevic (N)

Department of Gynecological Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Health Care Angela Boskin, 4270 Jesenice, Slovenia.

Gregor Sersa (G)

Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Health Sciences, University of Ljubljana, 1000 Ljubljana, Slovenia.

Sebastjan Merlo (S)

Department of Gynecological Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.

Maja Cemazar (M)

Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Faculty of Health Sciences, University of Primorska, 6000 Izola, Slovenia.

Classifications MeSH